Drug Type Antibody drug conjugate (ADC) |
Synonyms 35C + [1] |
Target |
Mechanism CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H42N6O11 |
InChIKeyFPFZTWMOHOCTJK-NVQXNPDNSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 1 | US | 28 May 2024 | |
Advanced cancer | Phase 1 | IT | 28 May 2024 | |
Advanced cancer | Phase 1 | DK | 28 May 2024 | |
Anaplastic Large-Cell Lymphoma | Phase 1 | DK | 28 May 2024 | |
Anaplastic Large-Cell Lymphoma | Phase 1 | US | 28 May 2024 | |
Anaplastic Large-Cell Lymphoma | Phase 1 | IT | 28 May 2024 | |
Hodgkin's Lymphoma | Phase 1 | US | 28 May 2024 | |
Hodgkin's Lymphoma | Phase 1 | IT | 28 May 2024 | |
Hodgkin's Lymphoma | Phase 1 | DK | 28 May 2024 | |
Lymphoma | Phase 1 | US | 14 May 2024 |